ACE inhibitors and ARBs are proven to slow kidney damage in diabetic nephropathy by reducing proteinuria. Used at maximum tolerated doses, they cut the risk of kidney failure. Avoid combining them with other RAAS blockers or NSAIDs. This is the standard of care in 2026.